Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 10/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999966 | 0.95 | CBFB (0.50) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL23999435 | 0.93 | MAPT (0.49) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL30180383 | 0.93 | MAPT (0.49) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL24006314 | 0.93 | SLC2A1 (0.49) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL24003878 | 0.93 | MAPKAPK2 (0.40) | SLC2A1MAPKAPK2KDR | |
| SCHEMBL23999749 | 0.92 | SLC2A1 (0.47) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL23999608 | 0.90 | MAPKAPK2 (0.54) | SLC2A1MAPKAPK2MAPTKDRMAPK10 | |
| SCHEMBL30180645 | 0.90 | MAPKAPK2 (0.54) | SLC2A1MAPKAPK2MAPTKDRMAPK10 | |
| SCHEMBL23999373 | 0.89 | SLC2A1 (0.43) | SLC2A1MAPKAPK2CBFBMAPTPOLB | |
| SCHEMBL24006297 | 0.88 | KDR (0.49) | SLC2A1MAPKAPK2CBFBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002511-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2025-01-02 | — | — | US | disclosed |
| EP-4426279-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118524833-A | AKT3 modulators | 乔治穆内公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115996939-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115867562-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146666-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146667-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021226517-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | SLC2A1 1038/4885MAPKAPK2 151/4885CBFB 3072/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | SLC2A1 1031/4885MAPKAPK2 138/4885CBFB 3251/4885 |
| US-20250002511-A1 | AKT3 MODULATORS | AKT3, PIK3C2A, PIK3C2B | SLC2A1 1582/4885MAPKAPK2 332/4885CBFB 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.